CYCC Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in US and UK.

$6.50
As of 06/23/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/28/2006
Outstanding shares:  9,234,110
Average volume:  101,213
Market cap:   $57,620,846
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    23254L603
ISIN:        US23254L6039
Sedol:      BLR6795

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   7.79
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%